Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey. more
Time Frame | IART | Sector | S&P500 |
---|---|---|---|
1-Week Return | -2.75% | -3.72% | -0.05% |
1-Month Return | 5.42% | -1.85% | 2.75% |
3-Month Return | 36.89% | -11.4% | 7.4% |
6-Month Return | -17.96% | -4.41% | 10.47% |
1-Year Return | -44.6% | 4.13% | 27.57% |
3-Year Return | -62.57% | 0.3% | 29.56% |
5-Year Return | -60.15% | 36.62% | 89.3% |
10-Year Return | 4.28% | 106.81% | 206.09% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 1.52B | 1.37B | 1.54B | 1.56B | 1.54B | [{"date":"2019-12-31","value":97.43,"profit":true},{"date":"2020-12-31","value":88.07,"profit":true},{"date":"2021-12-31","value":99.02,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.97,"profit":true}] |
Cost of Revenue | 564.68M | 520.83M | 597.81M | 587.36M | 653.18M | [{"date":"2019-12-31","value":86.45,"profit":true},{"date":"2020-12-31","value":79.74,"profit":true},{"date":"2021-12-31","value":91.52,"profit":true},{"date":"2022-12-31","value":89.92,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 952.88M | 851.03M | 944.64M | 970.31M | 888.39M | [{"date":"2019-12-31","value":98.2,"profit":true},{"date":"2020-12-31","value":87.71,"profit":true},{"date":"2021-12-31","value":97.35,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":91.56,"profit":true}] |
Gross Margin | 62.79% | 62.03% | 61.24% | 62.29% | 57.63% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":98.8,"profit":true},{"date":"2021-12-31","value":97.54,"profit":true},{"date":"2022-12-31","value":99.21,"profit":true},{"date":"2023-12-31","value":91.78,"profit":true}] |
Operating Expenses | 794.20M | 699.66M | 747.41M | 731.39M | 836.39M | [{"date":"2019-12-31","value":94.96,"profit":true},{"date":"2020-12-31","value":83.65,"profit":true},{"date":"2021-12-31","value":89.36,"profit":true},{"date":"2022-12-31","value":87.45,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | 178.98M | 151.37M | 197.23M | 238.92M | 111.53M | [{"date":"2019-12-31","value":74.91,"profit":true},{"date":"2020-12-31","value":63.36,"profit":true},{"date":"2021-12-31","value":82.55,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":46.68,"profit":true}] |
Total Non-Operating Income/Expense | (162.05M) | (120.13M) | (26.21M) | (62.70M) | (64.63M) | [{"date":"2019-12-31","value":-16205100000,"profit":false},{"date":"2020-12-31","value":-12013400000,"profit":false},{"date":"2021-12-31","value":-2621100000,"profit":false},{"date":"2022-12-31","value":-6270300000,"profit":false},{"date":"2023-12-31","value":-6463200000,"profit":false}] |
Pre-Tax Income | 60.10M | 93.52M | 214.68M | 213.89M | 81.07M | [{"date":"2019-12-31","value":28,"profit":true},{"date":"2020-12-31","value":43.56,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.64,"profit":true},{"date":"2023-12-31","value":37.76,"profit":true}] |
Income Taxes | 9.90M | (40.37M) | 45.60M | 33.34M | 13.33M | [{"date":"2019-12-31","value":21.72,"profit":true},{"date":"2020-12-31","value":-88.53,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":73.12,"profit":true},{"date":"2023-12-31","value":29.23,"profit":true}] |
Income After Taxes | 50.20M | 133.89M | 169.07M | 180.55M | 67.74M | [{"date":"2019-12-31","value":27.8,"profit":true},{"date":"2020-12-31","value":74.16,"profit":true},{"date":"2021-12-31","value":93.64,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":37.52,"profit":true}] |
Income From Continuous Operations | 50.20M | 133.89M | 169.07M | 180.55M | 67.74M | [{"date":"2019-12-31","value":27.8,"profit":true},{"date":"2020-12-31","value":74.16,"profit":true},{"date":"2021-12-31","value":93.64,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":37.52,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 50.20M | 133.89M | 169.07M | 180.55M | 67.74M | [{"date":"2019-12-31","value":27.8,"profit":true},{"date":"2020-12-31","value":74.16,"profit":true},{"date":"2021-12-31","value":93.64,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":37.52,"profit":true}] |
EPS (Diluted) | 2.74 | 2.45 | 3.18 | 3.35 | 3.10 | [{"date":"2019-12-31","value":81.79,"profit":true},{"date":"2020-12-31","value":73.13,"profit":true},{"date":"2021-12-31","value":94.93,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":92.54,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
IART | |
---|---|
Cash Ratio | 0.30 |
Current Ratio | 1.20 |
Quick Ratio | 0.73 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
IART | |
---|---|
ROA (LTM) | 3.02% |
ROE (LTM) | -0.42% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
IART | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.63 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.37 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
IART | |
---|---|
Trailing PE | NM |
Forward PE | 9.52 |
P/S (TTM) | 1.17 |
P/B | 1.20 |
Price/FCF | NM |
EV/R | 2.26 |
EV/Ebitda | 18.86 |
PEG | 0.79 |
Integra LifeSciences Holdings (IART) share price today is $23.71
Yes, Indians can buy shares of Integra LifeSciences Holdings (IART) on Vested. To buy Integra LifeSciences Holdings from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IART stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Integra LifeSciences Holdings (IART) via the Vested app. You can start investing in Integra LifeSciences Holdings (IART) with a minimum investment of $1.
You can invest in shares of Integra LifeSciences Holdings (IART) via Vested in three simple steps:
The 52-week high price of Integra LifeSciences Holdings (IART) is $45.42. The 52-week low price of Integra LifeSciences Holdings (IART) is $16.8.
The price-to-earnings (P/E) ratio of Integra LifeSciences Holdings (IART) is
The price-to-book (P/B) ratio of Integra LifeSciences Holdings (IART) is 1.20
The dividend yield of Integra LifeSciences Holdings (IART) is 0.00%
The market capitalization of Integra LifeSciences Holdings (IART) is $1.85B
The stock symbol (or ticker) of Integra LifeSciences Holdings is IART